Median latency intervals (horizontal line) with interquartile range (box) and overall range for 16 patients with Hodgkin's disease (HD) or non-Hodgkin lymphoma (NHL) who underwent autologous stem cell transplantation (SCT) compared with 131 patients with HD or NHL who did not receive SCT. For the 16 patients with HD or NHL undergoing SCT, the median latency interval to development of t-MDS/t-AML was 66 months from initial diagnosis and 22 months from SCT. This compares to the 65-month median latency interval from initial diagnosis to t-MDS/t-AML for HD and NHL patients not undergoing SCT. Circles indicate outliers.